Journal of Ethnopharmacology,
Journal Year:
2023,
Volume and Issue:
310, P. 116384 - 116384
Published: March 15, 2023
Yufeng
Ningxin
Tablet
(YNT)
is
a
traditional
Chinese
medicine
formula,
that
has
been
used
clinically
to
treat
migraine
for
many
years.
It
composed
of
one
herb
Pueraria
lobata
var.
(Willd.)
Ohwi
(Relevant
name:
Gegen).
Previously,
it
recorded
by
doctor
Gegen
could
be
as
migraine.
However,
the
underlying
mechanism
action
remains
investigated.It
was
explore
effect
and
YNT
on
based
network
pharmacology
experimental
verification.First,
with
pharmacology,
effective
chemical
components
target
genes
were
filtrated,
YNT-compound-migraine-targets
constructed.
The
protein-protein
interaction
(PPI)
literature
reports
combined
identify
potential
targets
in
treatment
Then,
representative
compounds
characterized
LC-MS/MS
major
identified.
Finally,
prediction
results
verified
animal
cell
experiments.7
bioactive
act
97
targets.
5
comprehensively
YNT.
key
therapeutic
pathways
collected
including
5-HT,
CGRP,
inflammation
nociceptive
factors,
NF-κB
signaling
pathway.
Animal
experiments
showed
increase
expression
level
5-HT
reduce
NF-κB,
c-fos
IL-1β.
inhibit
LPS-induced
neuroinflammation
BV2
cells
vitro.
Western
blotting
analysis
inhibited
phospho-NF-κB
levels.It
first
time
verify
consistency
between
metabolic
active
predicted
pharmacology.
Meanwhile,
studied
combining
vitro
vivo
experiments.
The Journal of Headache and Pain,
Journal Year:
2023,
Volume and Issue:
24(1)
Published: April 18, 2023
Migraine
is
a
severely
debilitating
disorder
that
affects
millions
of
people
worldwide.
Studies
have
indicated
activation
protease-activated
receptor-2
(PAR2)
in
the
dura
mater
causes
headache
responses
preclinical
models.
It
also
well
known
vasodilators
such
as
nitric
oxide
(NO)
donors
can
trigger
migraine
attacks
patients
but
not
controls.
In
current
study
we
examined
whether
PAR2
priming
to
NO
donor
glyceryl
trinitrate
(GTN).A
behavioral
model
was
used
where
stimuli
(PAR2
agonists:
2at-LIGRL-NH2
(2AT)
or
neutrophil
elastase
(NE);
and
IL-6)
were
applied
mouse
through
an
injection
made
at
intersection
lamdoidal
sagittal
sutures
on
skull.
Following
dural
injection,
periorbital
von
Frey
thresholds
facial
grimace
measured
until
their
return
baseline.
GTN
then
given
by
intraperitoneal
hypersensitivity
observed
they
returned
baseline.We
found
application
selective
agonist
onto
headache-related
WT
PAR2-/-
mice
with
no
differences
between
sexes.
Additionally,
2AT
caused
(1
mg/kg)
14
days
after
primary
stimulation.
showed
GTN.
We
tested
endogenous
protease
elastase,
which
cleave
activate
PAR2.
Dural
both
acute
mice.
Finally,
show
IL-6
identical
mice,
indicating
does
act
this
model.These
results
indicate
meninges
cause
donor,
support
further
exploration
novel
therapeutic
target
for
migraine.
Frontiers in Molecular Neuroscience,
Journal Year:
2024,
Volume and Issue:
17
Published: Aug. 7, 2024
Neurological
diseases
have
consistently
represented
a
significant
challenge
in
both
clinical
treatment
and
scientific
research.
As
research
has
progressed,
the
significance
of
mitochondria
pathogenesis
progression
neurological
become
increasingly
prominent.
Mitochondria
serve
not
only
as
source
energy,
but
also
regulators
cellular
growth
death.
Both
oxidative
stress
mitophagy
are
intimately
associated
with
mitochondria,
there
is
mounting
evidence
that
exert
pivotal
regulatory
influence
on
diseases.
In
recent
years,
been
notable
rise
prevalence
cerebral
ischemia/reperfusion
injury
(CI/RI),
vascular
dementia
(VaD),
Alzheimer’s
disease
(AD),
which
collectively
represent
public
health
concern.
Reduced
levels
observed
CI/RI,
VaD
AD.
The
improvement
pathology
demonstrated
through
increase
levels.
CI/RI
results
tissue
ischemia
hypoxia,
causes
stress,
disruption
blood–brain
barrier
(BBB)
damage
to
vasculature.
BBB
may
induce
or
exacerbate
some
extent.
addition,
inadequate
perfusion
due
altered
function
accumulation
amyloid
β
(Aβ)
thereby
contributing
exacerbating
AD
pathology.
Intravenous
plasminogen
activator
(tPA;
alteplase)
endovascular
thrombectomy
effective
treatments
for
stroke.
However,
narrow
window
opportunity
administration
tPA
thrombectomy,
markedly
elevated
incidence
disability
among
patients
CI/RI.
It
regrettable
currently
no
still
specific
drugs
Despite
availability
U.S.
Food
Drug
Administration
(FDA)-approved
first-line
AD,
including
memantine,
donepezil
hydrochloride,
galantamine,
these
agents
do
fundamentally
block
pathological
process
this
paper,
we
undertake
review
mechanisms
disorders,
summary
trials
conducted
proposal
new
strategy
targeted
disorders
based
stress.
Scope
The
anti‐neuroinflammatory
effect
of
a
novel
quinolyl‐substituted
analogue
resveratrol
(RV01)
on
lipopolysaccharide
(LPS)‐induced
microglial
activation
is
investigated,
as
well
the
possible
underlying
mechanisms.
Methods
and
results
Cell
viability
measured
using
an
MTT
assay.
Nitric
oxide
(NO)
release
determined
by
nitrite
interaction
between
RV01
inducible
nitric
synthase
(iNOS)
studied
molecular
docking.
Free
radical
scavenging
activity
reactive
oxygen
species
(ROS)
production
are
DPPH
reduction
assay
DCFH‐DA
Pretreatment
with
(1–30
µ
m
)
prior
to
LPS
(1
µg
mL
–1
stimulation
decreased
NO
iNOS
expression
without
observable
cytotoxicity.
reduced
mRNA
levels
secretion
tumor
necrosis
factor‐α
(TNF‐α)
interleukin‐6
(IL‐6).
also
inhibited
LPS‐induced
ROS
nicotinamide
adenine
dinucleotide
phosphate
(NADPH)
oxidase
activation.
Furthermore,
decreases
protein
toll‐like
receptor
4
(TLR4)
inhibits
mitogen‐activated
kinase
(MAPK)
nuclear
transcription
factor‐κB
(NF‐κB)
signaling
pathways.
Additionally,
conditioned
medium
from
microglia
co‐treated
alleviates
death
SH‐SY5Y
cells
induced
activated
N9
cells.
Lastly,
mouse
neuroinflammation
model
further
used
confirm
in
vivo.
Conclusion
These
show
that
suppresses
microglia‐mediated
protects
neurons
inflammatory
damage,
which
indicates
has
great
potential
nutritional
preventive
strategy
for
neuroinflammation‐related
diseases.
